Singulair

Singulair is a brand name of montelukast, approved by the FDA in the following formulation(s):

SINGULAIR (montelukast sodium - granule; oral)

• 
  Manufacturer: MERCK
  
  Approval date: July 26, 2002
  
  Strength(s): EQ 4MG BASE/PACKET ^[RLD]

SINGULAIR (montelukast sodium - tablet, chewable; oral)

• 
  Manufacturer: MERCK
  
  Approval date: February 20, 1998
  
  Strength(s): EQ 5MG BASE ^[RLD]


• 
  Manufacturer: MERCK
  
  Approval date: March 3, 2000
  
  Strength(s): EQ 4MG BASE
  

SINGULAIR (montelukast sodium - tablet; oral)

• 
  Manufacturer: MERCK
  
  Approval date: February 20, 1998
  
  Strength(s): EQ 10MG BASE ^[RLD]

Has a generic version of Singulair been approved?

No. There is currently no therapeutically equivalent version of Singulair available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Singulair. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
  Patent 5,565,473
  Issued: October 15, 1996
  Inventor(s): Belley; Michel L. & Leger; Serge & Labelle; Marc & Roy; Patrick & Xiang; Yi B. & Guay; Daniel
  Assignee(s): Merck Frosst Canada, Inc.
  Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
  
  Patent expiration dates:
  
  
  • February 3, 2012
    
    ✓ 
    Patent use: PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • February 3, 2012
    
    ✓ 
    Patent use: PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • February 3, 2012
    
    ✓ 
    Patent use: ASTHMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • August 3, 2012
    
    ✓ 
    Patent use: ASTHMA
    ✓ 
    Pediatric exclusivity
  
  
  
  • August 3, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Granule formation
  Patent 8,007,830
  Issued: August 30, 2011
  Inventor(s): Down; Brian
  Assignee(s): Merck Frosst Canada & Co.
  The present invention relates to oral granules of montelukast sodium.
  
  Patent expiration dates:
  
  
  • October 24, 2022
    
    ✓ 
    Drug product
  
  

See also...

• Singulair Consumer Information (Drugs.com)
• Singulair Consumer Information (Wolters Kluwer)
• Singulair Chewable Tablets Consumer Information (Wolters Kluwer)
• Singulair Granules Consumer Information (Wolters Kluwer)
• Singulair Consumer Information (Cerner Multum)
• Singulair Advanced Consumer Information (Micromedex)
• Singulair AHFS DI Monographs (ASHP)
• Montelukast Consumer Information (Wolters Kluwer)
• Montelukast Chewable Tablets Consumer Information (Wolters Kluwer)
• Montelukast Granules Consumer Information (Wolters Kluwer)
• Montelukast Consumer Information (Cerner Multum)
• Montelukast Advanced Consumer Information (Micromedex)
• Montelukast Sodium AHFS DI Monographs (ASHP)